Relmada Therapeutics, Inc. (RLMD)

Market Cap	758.34M +5,355.7%
Revenue (ttm)	n/a
Net Income	-58.88M
EPS	-1.10
Shares Out	104.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,371
Open	7.18
Previous Close	7.17
Day's Range	7.15 - 7.32
52-Week Range	0.52 - 8.00
Beta	0.43
Analysts	Strong Buy
Price Target	12.80 (+77.04%)
Earnings Date	May 12, 2026

About RLMD

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: RLMD
• Website: https://www.relmada.com

Analyst Summary

According to 5 analysts, the average rating for RLMD stock is "Strong Buy." The 12-month stock price target is $12.8, which is an increase of 77.04% from the latest price.

Price Target

$12.8

(77.04% upside)

Analyst Consensus: Strong Buy